āĻšā§āĻŽI7G âĸ FRA
add
Ipsen SA
⧝⧝.ā§Ēā§ĻâŦ
ā§Šā§Ļ āĻāĻĒā§āϰāĻŋ, ā§§ā§Ļ:ā§Ģ⧝:ā§Ēā§Ē PM GMT +⧍ · EUR · FRA · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
ā§¯ā§Ž.ā§ā§ĢâŦ
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
⧝⧝.ā§Ēā§ĻâŦ - ⧝⧝.ā§Ēā§ĻâŦ
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
⧝ā§Ļ.⧍ā§ĻâŦ - ⧧⧍ā§Ģ.ā§Šā§ĻâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§Žā§Ēā§Š.⧍ā§Ē āĻā§ EUR
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
ā§Ē.ā§Ļā§Ļ
P/E āĻ
āύā§āĻĒāĻžāϤ
ā§¨ā§Š.⧍⧝
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
ā§§.ā§Ēā§§%
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
EPA
āĻŦāĻžāĻāĻžāϰ āϏāĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
(EUR) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ⧝⧧.ā§§ā§Ē āĻā§ | â |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ā§Ģā§Ļ.ā§§ā§Ļ āĻā§ | â |
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§Ģ.ā§ā§Ļ āĻā§ | â |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | ā§Ŧ.⧍ā§Ģ | â |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | â | â |
EBITDA | ā§Šā§Ģ.ā§Ēā§¯Â āĻā§ | â |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | ⧧⧝.ā§Ēā§§% | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(EUR) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ā§Ŧā§.ā§¯ā§¨Â āĻā§ | ā§¨ā§Ž.ā§Ģā§Ē% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Ŧā§Ēā§Š.⧝ā§Ļ āĻā§ | ā§§.ā§Žā§Ē% |
āĻŽā§āĻ āĻĻāĻžā§ | ⧍⧍ā§Ģ.ā§ā§¨Â āĻā§ | -⧝.ā§Ŧā§Ž% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Ēā§§ā§Ž.ā§§ā§ŽÂ āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§Ž.⧍ā§Â āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§§.⧝ā§Ģ | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§§ā§Ļ.ā§Ļā§% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | ā§§ā§Š.ā§Žā§Ļ% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
(EUR) | āĻĄāĻŋāϏ⧠⧍ā§Ļ⧍ā§Ēinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | ā§Ģ.ā§ā§Ļ āĻā§ | â |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | ⧍⧍.ā§Ēā§ŽÂ āĻā§ | â |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§¨ā§Š.ā§Žā§ŽÂ āĻā§ | â |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ā§§ā§Ļ.ā§¯ā§§Â āĻā§ | â |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | ā§§ā§Ļ.ā§Ģā§Ļ āĻā§ | â |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| ā§Ŧ.ā§Žā§Â āĻā§ | â |
āϏāĻŽā§āĻĒāϰā§āĻā§
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
āϏāĻŋāĻāĻ
āϏā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§ā§āĻā§
⧧⧝⧍⧝
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§Ģ,ā§Šā§Ģā§Ž